

| | |
|-------------------------|----------------------------------------------|
| Reference: | FOI.14209.24 |
| Subject: | Urothelial and Endometrial cancer treatments |
| Date of Request: | 12 April 2024 |

Requested:

1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
 - Atezolizumab (Tecentriq)
 - Avelumab (Bavencio)
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Other active systemic anti-cancer therapy
 - Palliative care only

2. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

3. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
 - Dostarlimab (Jemperli)
 - Hormone therapy (Progesterone or Letrozole)
 - Pembrolizumab (Keytruda) monotherapy
 - Pembrolizumab + Lenvatinib (Keytruda + Lenvima)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Any other SACT

4. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for palliative care in question 1, hormone therapy in question 3 and the information requested in question 4, the UHB would need to undertake a manual trawl of patient medical records that are receiving palliative care and those receiving treatment for

endometrial cancer, to identify any information that would fulfil these parts of your request, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

Where the figures in the tables for questions 1 and 3 have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides, within the table below, the number of Urothelial cancer patients treated with the listed treatments, during the period 1 January to 31 March 2024.

| Treatment | Number |
|------------------------------------------------------|------------------------------|
| Atezolizumab (Tecentriq) | 7 |
| Avelumab (Bavencio) | * |
| Carboplatin single agent or in any other combination | 0 |
| Carboplatin with Gemcitabine | * |
| Carboplatin with Paclitaxel | 0 |
| Cisplatin single agent or in any other combination | 0 |
| Cisplatin with Gemcitabine | 9 |
| Nivolumab (Opdivo) | 0 |
| Pembrolizumab (Keytruda) | 0 |
| Other active systemic anti-cancer therapy | 0 |
| Palliative care only | Section 12 exemption applied |

2. The UHB confirms that it does provide Systemic Anti-Cancer Therapy (SACT) treatments for endometrial cancer.
3. The UHB provides, within the table below, the number of Endometrial cancer patients treated with the listed treatments, during the period 1 January to 31 March 2024.

| Treatment | Number |
|---------------------------------------------|------------------------------|
| Dostarlimab (Jemperli) | * |
| Hormone therapy (Progesterone or Letrozole) | Section 12 exemption applied |

| | |
|---------------------------------------------------------------------------------------------------------|---|
| Pembrolizumab (Keytruda) monotherapy | 0 |
| Pembrolizumab + Lenvatinib (Keytruda + Lenvima) | 0 |
| Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) | 9 |
| Any other SACT | * |

4. Section 12 exemption applied.